AbbVie Inc. said Tuesday that it will partner with Scripps Research to develop new COVID-19 antivirals. “Our SARS-CoV-2 research program has the potential to impact significantly the ongoing gaps in patient needs to move from pandemic to endemic COVID-19,” Peter Schultz, president and CEO of Scripps Research, said in a news release. There are two authorized COVID-19 antivirals: Pfizer Inc.’s Paxlovid, and Merck & Co. Inc.’s molnupiravir. AbbVie’s stock has gained 12.3% since the beginning of the year, while the S&P 500 is down 12.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
